111669-15-9

Basic information

• Product Name: 4-CHLORO-2,6-DIPYRROLIDIN-1-YLPYRIMIDINE
• Synonyms: 4-CHLORO-2,6-DIPYRROLIDIN-1-YLPYRIMIDINE;2,4-di(1-pyrrolidinyl)-6-chloropyrimidine
• CAS NO: 111669-15-9
• Molecular Formula: C₁₂H₁₇ClN₄
• Molecular Weight: 252.74
• Mol File: 111669-15-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 79-82 °C
• Boiling Point: 444.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.283±0.06 g/cm3(Predicted)
• PKA: 4.27±0.50(Predicted)
• CAS DataBase Reference: 4-CHLORO-2,6-DIPYRROLIDIN-1-YLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2,6-DIPYRROLIDIN-1-YLPYRIMIDINE(111669-15-9)
• EPA Substance Registry System: 4-CHLORO-2,6-DIPYRROLIDIN-1-YLPYRIMIDINE(111669-15-9)

Safety Data

• Hazardous Substances Data: 111669-15-9(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 154117-92-7 2,4-dichloro-6-(pyrrolidin-1-yl)pyrimidine 

Downstream Products

• 111641-17-9 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)-pyrimidine 
• 157012-18-5 7-methyl-6-phenyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine 
• 172035-68-6 U-101033 
• 157012-37-8 6-phenyl-7-phenylmethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine 
• 157014-30-7 N-(4'-methoxyphenyl)-2,6-di-1-pyrrolidinyl-4-pyrimidinamine 
• 262614-53-9 4-[4-(4-nitrophenyl)-1-piperazinyl]-2,6-di(1-pyrrolidinyl)pyrimidine 
• 110101-66-1 16α-methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione 
• 182146-03-8 7-methyl-6-(trifluoromethyl)-2,4-dipyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Facile aromatic nucleophilic substitution (SNAr) reactions in ionic liquids: An electrophile-nucleophile dual activation by [Omim]Br for the reaction

A facile aromatic nucleophilic substitution (SNAr) reaction in recyclable [Omim]Br under relatively mild conditions has been described. An electrophile-nucleophile dual activation by [Omim]Br is also discovered based on control experiments, 1H NMR and IR spectroscopies. This chemistry provides an efficient and metal-free approach for the generation of Caryl-X (XS, N, O) bonds, many of which are significant synthetic intermediates or drugs, making this methodology attractive to both synthetic and medicinal chemistry.

TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS

The present invention relates to triaminopyrimidine derivatives of formula (I) where Y, R3, W, R4a, R5a, R4b, R5b, n and m are variable. These compounds have CDC25 phosphatase-inhibiting activity and can therefore be used as drugs in diseases in which CDC

Biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel eburnamenine derivatives of formula (I): STR1 wherein R1 and R2 as well as R3 and R4, independently from each other, stand for hydrogen, C2-6 alkyl group, C2-6 alkenyl group; or a C3-10 alicyclic group involving 1 to 3 rings, and this latter group may be substituted by a C1-6 alkyl or C2-6 alkenyl group; or R1 and R2 and/or R3 and R4, together with the adjacent nitrogen atom and optionally with an additional oxygen or nitrogen atom, form a 4- to 6-membered, saturated or unsaturated cyclic group which may be substituted by a C1-6 alkyl or C2-6 alkenyl group; two of X, Y and Z are nitrogen whereas the third of them means a methine group; n is 1 or 2; W means oxygen or two hydrogen atoms; and the wavy line means α-/α-, α-/β- or β-/α- steric position, as well as their acid addition salts and solvates. The invention further relates to pharmaceutical compositions containing the above compounds as well as a process for preparing the compounds of formula (I). The compounds of formula (I) possess antioxidant effect and therefore, they are useful for inhibiting the peroxidation of lipids occurring in mammals (including human).